Christophe BAPST

Former CEO, Investor in start-ups

Search for:

Recent Posts

Dry AMD: SeaBeLife achieves highly promising preclinical efficacy results for SBL03, without injections into eye
SeaBeLife receives Orphan Drug Designation (ODD) from EMA for treatment of acute liver injuries
27th Carrés 2023 – SEABELIFE Innovation Award
LSX Inv€$tival Showcase
SeaBeLife raises €1.2 M ($1.28 M) from iXLife fund and historical investors

A biotech company developing a range of drugs designed to block cell necrosis to treat serious diseases affecting major organs, without therapeutic alternatives

Contact
Recrutement

Français